Advertisement

Effects of Hormone Replacement Therapy on Low Bone Mineral Density in Adolescents and Young Women with Hypogonadism: Comparison of Oral and Transdermal 17 Beta-Estradiol Administration

      ABSTRACT

      Study Objective

      To evaluate the effects of physiological dose 17 beta-estradiol (E2) replacement on low bone mineral density (BMD) and compare the results of oral and transdermal (TD) E2 administration in adolescents and young women with hypogonadism

      Design, Setting, and Participants

      We retrospectively reviewed the medical records of patients aged 15 to 24 years who were diagnosed with hypogonadism, who had begun receiving oral or TD E2 replacement, and whose initial dual-energy X-ray absorptiometry scan detected a lumbar spine BMD Z-score of -1 or lower between 2014 and 2018. The patients were divided into 2 groups according to the E2 route of administration as those who received 2 mg orally (Group 1) and 0.1 mg TD (Group 2).

      Interventions

      None

      Main Outcome Measure

      BMD scans of the patients at baseline and repeated within 2 years after E2 replacement

      Results

      In total, 43 patients who met the inclusion criteria were included in the study. Two groups did not differ for BMD scores at baseline. A significant improvement in BMD was observed with physiological dose E2 replacement in both groups. Mean BMD Z-score increased by +0.7 (95% CI, 0.47-0.93) in response to TD E2 administration, compared with +0.41 (95% CI, 0.25-0.58) during oral E2 replacement (P = .037).

      Conclusion

      We conclude that physiological dose E2 replacement, even within a short period of 2 years, has a significant beneficial effect on bone mass acquisition on the lumbar spine. Our study also demonstrates the possible superiority of TD E2 replacement over the oral route in increasing lumbar spine BMD.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Pediatric and Adolescent Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Committee Opinion No. 605: Primary ovarian insufficiency in adolescents and young women.
        Obstet Gynecol. 2014; 124: 193-197
        • Popat VB
        • Calis KA
        • Vanderhoof VH
        • et al.
        Bone mineral density in estrogen-deficient young women.
        J Clin Endocrinol Metab. 2009; 94: 2277-2283
        • Bachelot A
        • Rouxel A
        • Massin N
        • et al.
        Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure.
        Eur J Endocrinol. 2009; 161: 179-187
        • Webber L
        • Davies M
        • Anderson R
        • et al.
        ESHRE Guideline: management of women with premature ovarian insufficiency.
        Hum Reprod. 2016; 31: 926-937
      2. Committee Opinion No. 698: Hormone therapy in primary ovarian insufficiency.
        Obstet Gynecol. 2017; 129: e134-e141
        • Crofton PM
        • Evans N
        • Bath LE
        • et al.
        Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover.
        Clin Endocrinol (Oxf). 2010; 73: 707-714
        • Cartwright B
        • Robinson J
        • Seed PT
        • et al.
        Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on bone mineral density.
        J Clin Endocrinol Metab. 2016; 101: 3497-3505
        • Divasta AD
        • Gordon CM
        Hormone replacement therapy and the adolescent.
        Curr Opin Obstet Gynecol. 2010; 22: 363-368
        • Goodman M
        Are all estrogens created equal? A review of oral vs. transdermal therapy.
        J Womens Health (Larchmt). 2012; 21: 161-169
        • Torres-Santiago L
        • Mericq V
        • Taboada M
        • et al.
        Metabolic effects of oral versus transdermal 17beta-estradiol (E2): a randomized clinical trial in girls with Turner syndrome.
        J Clin Endocrinol Metab. 2013; 98: 2716-2724
        • Singhal V
        • Ackerman KE
        • Bose A
        • et al.
        Impact of route of estrogen administration on bone turnover markers in oligoamenorrheic athletes and its mediators.
        Clin Endocrinol Metab. 2019; 104: 1449-1458
        • Misra M
        • Katzman D
        • Miller KK
        • et al.
        Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa.
        J Bone Miner Res. 2011; 26: 2430-2438
        • Ackerman KE
        • Singhal V
        • Baskaran C
        • et al.
        Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomized clinical trial.
        Br J Sports Med. 2019; 53: 229-236
        • Conway GS
        • Kaltsas G
        • Patel A
        • et al.
        Characterization of idiopathic premature ovarian failure.
        Fertil Steril. 1996; 65: 337-341
        • Gordon CM
        • Bachrach LK
        • Carpenter TO
        • et al.
        Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions.
        J Clin Densitom. 2008; 11: 43-58
        • Miller KK
        • Klibanski A
        Clinical review 106: Amenorrheic bone loss.
        J Clin Endocrinol Metab. 1999; 84: 1775-1783
        • Shuhart CR
        • Yeap SS
        • Anderson PA
        • et al.
        Executive summary of the 2019 ISCD Position Development Conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics.
        J Clin Densitom. 2019; 22: 453
        • Imai K
        • Ohnishi I
        • Matsumoto T
        • et al.
        Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method.
        Osteoporos Int. 2009; 20: 801-810
        • Imai K:
        Vertebral fracture risk and alendronate effects on osteoporosis assessed by a computed tomography-based nonlinear finite element method.
        J Bone Miner Metab. 2011; 29: 645-651
        • Mishell Jr, DR
        • Nakamura RM
        • Crosignani PG
        • et al.
        Serum gonadotropin and steroid patterns during the normal menstrual cycle.
        Am J Obstet Gynecol. 1971; 111: 60-65
        • MacNaughton J
        • Banah M
        • McCloud P
        • et al.
        Age-related changes in the follicle-stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age.
        Clin Endocrinol (Oxf). 1992; 36: 339-345
        • Steingold KA
        • Matt DW
        • DeZiegler D
        • et al.
        Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.
        J Clin Endocrinol Metab. 1991; 73: 275-280